Back to News
Market Impact: 0.25
Cemsidomide Shows Immune Activation In C4 Therapeutics' Myeloma Study
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
C4 Therapeutics presented new biomarker data from Phase 1 studies of cemsidomide in combination with dexamethasone and from a Phase 1b trial with Pfizer's elranatamab (ELREXFIO). The update supports continued clinical development of cemsidomide in targeted protein degradation, though the provided article excerpt does not include efficacy, safety, or financial results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
CCCC0.45
More News
- Shares of Akamai surge after deal with Anthropic. What Wall Street is saying
- Wall Street Week | China’s Trade Reckoning, Syracuse’s Second Chance, Humanoids in Healthcare
- ‘U.S. trade policy is damaging the U.S. auto industry’: Canada’s purchase of American cars hits new low as Trump’s tariffs backfire on U.S. automakers
- Yields keep rising, Novo's tough week, why cat product sales are surging and more in Morning Squawk
- Beware borrowing costs: The jump in yields could hit these debt-laden stocks the most
- Why Akamai Stock Is Up Today